Roche to pay dollars 5.3bn for Syntex
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.NEW YORK - Roche Holding, the big Swiss pharmaceuticals group that has been shopping for a US partner, stunned the industry yesterday by buying a struggling US drug-maker and paying a huge premium for it, writes Larry Black.
Syntex Corp - whose two core anti-inflammatory drugs, Naprosyn and Anaprox, recently lost patent protection - agreed to an all-cash merger worth dollars 5.3bn. That figure values the deal at dollars 24 a share, almost 60 percent more than its opening share price yesterday would have suggested.
Syntex closed up dollars 8 1/2 at dollars 23 3/4 , and sent shares of other distressed US drug companies soaring. Soon after the closing, Eastman Kodak scheduled an important announcement for today that some analysts said could involve a plan to sell or spin off its Sterling Drugs division.
Kodak's share jumped more than 7 per cent on the speculation, while some pharmaceutical issues - notably Upjohn - gained almost as much on merger rumours.
Roche, which first expressed interest in Syntex more than five years ago after losing in a dollars 4.6bn bidding war for Sterling, said the price it was paying for the California company was 'fair', based on an independent investment banking opinion. But industry experts said they were puzzled by the large premium - five times book value.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments